List view / Grid view
National Institue for Health and Care Excellence (NICE)
Nivolumab together with chemotherapy has been recommended in NICE final draft guidance for treatment of gastroesophageal cancer.
The regulatory body said that due to uncertainties surrounding the long-term effectiveness of nivolumab (Opdivo), its cost-effectiveness estimates are too high.
The UK’s National Institute for Health and Care Excellence, NICE, recommends the use of fremanezumab on the NHS for preventing chronic migraine.
The National Institute for Health and Care Excellence (NICE) has stated that combined use of the drugs pembrolizumab and axitinib is not recommended for untreated advanced renal cell carcinoma in adults.